| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.10. | FDA approves Teva's monthly injection of olanzapine for schizophrenia | ||
| 12.10. | FDA approves Asahi Kasei's Hovilpri for refractory HSV | ||
| 12.10. | Perceptive, Nucleus partner to support radiopharmaceutical development | ||
| 09.10. | Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO | ||
| 09.10. | Roche's Tecentriq snags FDA label expansion in type of colon cancer | ||
| 09.10. | Bio-Techne opens GMP small molecule facility in Bristol, UK | ||
| 09.10. | Biohaven partners with Ono in $100m IgG degrader deal | ||
| 08.10. | Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout | ||
| 08.10. | Change lifestyle before giving children weight loss medication, WHO says | ||
| 08.10. | FDA approves Pfizer's Tukysa regimen for metastatic breast cancer | ||
| 08.10. | 10x Genomics and Fred Hutch partner on cancer technologies | ||
| 07.10. | CAR-T specialist Caribou culls pipeline and seeks exit deal | ||
| 07.10. | KymaThera pulls in $80m to bring breast cancer drug to clinic | ||
| 07.10. | Rocket receives $150m credit facility to advance cardiovascular portfolio | ||
| 07.10. | Gilead Sciences signs five-year DevOps agreement with Cognizant | ||
| 06.10. | Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout | ||
| 06.10. | Lilly deepens ties with Gate Bioscience in $870m deal expansion | ||
| 06.10. | Alector shares up after sealing $1.27bn Roche Parkinson's disease license deal | ||
| 06.10. | CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug | ||
| 06.10. | Pacira partners with Molteni for Exparel commercialisation | ||
| 06.10. | AstraZeneca opens new R&D centre in Cambridge, US | ||
| 05.10. | Scientists claim Nobel Prize for approach behind light-activated gene therapy | ||
| 05.10. | FDA approves expanded indication for Lilly's Jaypirca | ||
| 05.10. | Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US | ||
| 02.10. | AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact |